



BRITISH COLUMBIA
CENTRE *for* EXCELLENCE
in HIV/AIDS

B.C. HIV/AIDS Drug Treatment Program

Monthly Report

February 2024





© 2024 BC Centre for Excellence in HIV/AIDS

DISCLAIMER: This document is published by the British Columbia Centre for Excellence in HIV/AIDS (BC-CfE) as an overview of the activities of the BC-CfE's Drug Treatment Program. All information is generated from a live database maintained by the BC-CfE that houses data for clinical and virological outcome studies of patients receiving antiretroviral therapy.

This database is updated on a regular basis. Figures and tables provided in this Monthly Report represent the best estimates available at the time this document was generated.

Please be advised that information provided in this document is provided in good faith and is derived from sources believed to be accurate and up-to-date at the report's date of publication. The BC Centre for Excellence in HIV/AIDS nevertheless reserves the right to update this information at any time.

Information provided here at this time, is being provided freely, and no kind of agreement or contract is created between you and the authors. The authors cannot be responsible for any violations should you reproduce or republish the information contained herein.

Please note that the figures and graphs in this document are best viewed in colour.

BC Centre for Excellence in HIV/AIDS Drug Treatment Program

St. Paul's Hospital
687 - 1081 Burrard Street
Vancouver, BC
V6Z 1Y6

Tel: 604.806.8515
Fax: 604.806.9044

Physician Drug Hotline: 1.800.665.7677
St. Paul's Hospital Pharmacy Hotline: 1.888.511.6222
Website: www.bccfe.ca
Email: info@bccfe.ca

Funding for the BC Centre for Excellence in HIV/AIDS is provided through Pharmacare and the Provincial Health Services Authority (PHSA)





EXECUTIVE SUMMARY

A key component of the BC Centre for Excellence in HIV/AIDS' (BC-CfE) mandate is to monitor the impact of HIV/AIDS in British Columbia. The BC-CfE provides essential information to local health authorities, treating physicians, and the community at large on an ongoing basis. The HIV/AIDS Drug Treatment Program (DTP) Update is one example of the BC-CfE's commitment to people living with HIV throughout the Province of British Columbia.

The DTP distributes anti-HIV drugs at no cost to eligible British Columbians. The DTP Update provides an important overview of available anti-HIV drugs, common drug combinations and distribution of active DTP participants throughout the province.

DTP participants are typically followed at three-monthly intervals at which time routine blood sampling is performed. Information from all recipients is entered into a database, providing data for clinical and virological outcome studies of patients receiving antiretroviral therapy. These studies form the basis of ongoing revisions to the BC-CfE's treatment guidelines.





TABLE OF CONTENTS

1. List of Figures

- 1.1 Distribution of males and females on antiretroviral therapy in British Columbia by Health Authority
- 1.2 Distribution of Participants in HIV/AIDS Drug Treatment Program by Regimen Category
- 1.3 Percent Distribution of Participants in HIV/AIDS Drug Treatment Program by Regimen Category
- 1.4 BC-CfE Enrolment: Net Number of New Antiretroviral Participants
- 1.5 BC-CfE Enrolment: New Antiretroviral Participants
- 1.6 Percent Distribution of Active Participants by CD4 Count
- 1.7 Percent Distribution of Inactive Participants by CD4 Count
- 1.8 Active and Inactive Participants
- 1.9 Percent Distribution of Participants on ARV Therapy by Number of Drugs
- 1.10 Distribution of Participants on Nucleoside/Nucleotide Analogues by Ingredient
- 1.11 Distribution of Participants on Nucleoside/Nucleotide Analogues at the time of first start of ARV Therapy by Ingredient
- 1.12 Distribution of Participants on Protease Inhibitor by Ingredient
- 1.13 Distribution of Participants on Protease Inhibitor at the time of first start of ARV Therapy by Ingredient
- 1.14 Distribution of Participants on Non-Nucleosides by Ingredient
- 1.15 Distribution of Participants on Non-Nucleosides at the time of first start of ARV Therapy by Ingredient
- 1.16 Distribution of Participants on Entry/Integrase Inhibitors by Ingredient
- 1.17 Distribution of Participants on Entry/Integrase Inhibitors at the time of first start of ARV Therapy by Ingredient
- 1.18 Baseline CD4 for Antiretroviral First Starts
- 1.19 DTP Participants with PVL Measurement within previous five years, and never on ART
- 1.20 Cumulative Resistance Testing Results by Resistance Category
- 1.21 Percent of Participants ever on ARV - Resistance Testing Results by Resistance Category

2. List of Tables

- 2.1 Duration of ARV treatment in the Province of BC, 1987-2022 (for HIV+ persons currently on treatment)
- 2.2 Median Viral Load and CD4 for Active patients in Drug Treatment Program
- 2.3 Median Viral Load and CD4 for Inactive patients in Drug Treatment Program
- 2.4 BC-CfE Enrolment
- 2.5 Percent Distribution of Participants on ARV Therapy by Number of Drugs
- 2.6 Number of Participants on Nucleoside/Nucleotide Analogues by Ingredient
- 2.7 Number of Participants on Protease Inhibitor by Ingredient
- 2.8 Number of Participants on Non-Nucleosides by Ingredient
- 2.9 Number of Participants on Entry/Integrase Inhibitors by Ingredient
- 2.10 Distribution of Participants in HIV/AIDS Drug Treatment Program by Regimen Category
- 2.11 Baseline CD4 for Antiretroviral First Starts
- 2.12 DTP Participants with PVL Measurement within previous five years, and never on ART





Table of Contents, cont'd...

3. Health Authority Maps

- 3.1 Distribution of HIV/AIDS Drug Treatment Program Active Participants
- 3.2 Interior Health Authority & Kelowna
- 3.3 Fraser Health Authority & Surrey
- 3.4 Vancouver Coastal Health Authority & Vancouver
- 3.5 Vancouver Island Health Authority & Victoria
- 3.6 Northern Health Authority & Prince George

4. Health Authority Tables

INTERIOR HEALTH

- 4.1 Distribution of Participants in BC-CfE Registries by Age and Sex at birth
- 4.2 Distribution of Participants in BC-CfE Registries by Treatment Duration
- 4.3 Distribution of ARV Prescribers in BC-CfE Registries

FRASER HEALTH

- 4.4 Distribution of Participants in BC-CfE Registries by Age and Sex at birth
- 4.5 Distribution of Participants in BC-CfE Registries by Treatment Duration
- 4.6 Distribution of ARV Prescribers in BC-CfE Registries

VANCOUVER COASTAL

- 4.7 Distribution of Participants in BC-CfE Registries by Age and Sex at birth
- 4.8 Distribution of Participants in BC-CfE Registries by Treatment Duration
- 4.9 Distribution of ARV Prescribers in BC-CfE Registries

VANCOUVER ISLAND

- 4.10 Distribution of Participants in BC-CfE Registries by Age and Sex at birth
- 4.11 Distribution of Participants in BC-CfE Registries by Treatment Duration
- 4.12 Distribution of ARV Prescribers in BC-CfE Registries

NORTHERN HEALTH

- 4.13 Distribution of Participants in BC-CfE Registries by Age and Sex at birth
- 4.14 Distribution of Participants in BC-CfE Registries by Treatment Duration
- 4.15 Distribution of ARV Prescribers in BC-CfE Registries

ABORIGINAL

- 4.16 Distribution of Indigenous Participants in BC-CfE Registries by Health Service Delivery Area and Sex at birth

5. Appendix

- 5.1 Drug Names and Definitions






1.1 Distribution of males and females on antiretroviral therapy in British Columbia by Health Authority

February 2024

N = 7659



Health Authority	Male	Female	All
FRASER	1551	485	2036
INTERIOR	467	117	584
NORTHERN	163	85	248
VANCOUVER COASTAL	3302	456	3758
VANCOUVER ISLAND	846	168	1014
	6329	1311	7640
		Unknown/not stated:	19
		Total:	7659

Definitions:

On antiretroviral therapy defined as being on treatment in the current month


Unknown/not stated defined as being on treatment in the current month, and city of residence unknown

Male & Female refer to Sex at birth





1.2 Distribution of Participants in HIV/AIDS Drug Treatment Program by Regimen Category (February 2019 - February 2024)




Notes:

Regimen categories may contain a small number of participants with undetermined regimen, due to medication change(s) within the month





1.3 Percent Distribution of Participants in HIV/AIDS Drug Treatment Program by Regimen Category (February 2019 - February 2024)




Notes:

Regimen categories may contain a small number of participants with undetermined regimen, due to medication change(s) within the month






1.4 BC-CfE Enrolment: Net Number of New Antiretroviral Participants (February 2019 - February 2024)






1.5 BC-CfE Enrolment: New Antiretroviral Participants (February 2019 - February 2024)






1.6 Percent Distribution of Active Participants by CD4 Count (February 2019 - February 2024)






1.7 Percent Distribution of Inactive Participants by CD4 Count (February 2019 - February 2024)






1.8 Active and Inactive Participants (February 2019 - February 2024)






1.9 Percent Distribution of Participants on ARV Therapy by Number of Drugs (February 2019 - February 2024)






1.10 Distribution of Participants on Nucleoside/Nucleotide Analogues by INGREDIENT (February 2019 - February 2024)






1.11 Distribution of Participants on Nucleoside/Nucleotide Analogues at the time of first start of ARV Therapy by INGREDIENT

(February 2019 - February 2024)






1.12 Distribution of Participants on Protease Inhibitor by INGREDIENT (February 2019 - February 2024)






1.13 Distribution of Participants on Protease Inhibitor at the time of first start of ARV Therapy by INGREDIENT

(February 2019 - February 2024)






1.14 Distribution of Participants on Non-Nucleosides by INGREDIENT
(February 2019 - February 2024)






1.15 Distribution of Participants on Non-Nucleosides at the time of first start of ARV Therapy by INGREDIENT

(February 2019 - February 2024)






1.16 Distribution of Participants on Entry/Integrase Inhibitors by INGREDIENT (February 2019 - February 2024)






1.17 Distribution of Participants on Entry/Integrase Inhibitors
at the time of first ARV Therapy by INGREDIENT

(February 2019 - February 2024)






1.18 Baseline CD4 for Antiretroviral First Starts
(February 2019 - February 2024)






1.19 DTP Participants with PVL Measurement within previous five years, and never on ART (February 2019 - February 2024)






1.20 Cumulative Resistance Testing Results by Resistance Category (February 2019 - February 2024)





1.21 Percent of Participants ever on ARV - Resistance Testing Results by Resistance Category (February 2019 - February 2024)





**2.1 Duration of ARV treatment in the Province of BC, 1987-2024
(for HIV+ persons currently on treatment)**

Start Year	Duration (years) Median	Male	Female	All	Current CD4 (n)	Median	Current PVL (n)	Median	Current ARV Median
1987	32	4	0	4	1	780	4	<40	4
1988	33	4	0	4	1	510	4	<40	4
1989	31	49	1	50	16	480	48	<40	3
1990	29	50	1	51	25	550	47	<40	3
1991	30	35	3	38	16	540	37	<40	3
1992	29	49	5	54	22	605	52	<40	3
1993	28	109	14	123	65	560	120	<40	3
1994	27	65	11	76	44	585	74	<40	3
1995	26	114	20	134	66	630	124	<40	3
1996	25	292	46	338	170	590	309	<40	3
1997	23	252	29	281	143	570	249	<40	3
1998	23	172	34	206	115	580	183	<40	3
1999	22	145	39	184	107	600	166	<40	3
2000	22	111	24	135	78	625	119	<40	3
2001	22	106	24	130	71	590	119	<40	3
2002	21	114	20	134	74	590	124	<40	3
2003	20	130	26	156	84	590	137	<40	3
2004	19	137	35	172	97	650	152	<40	3
2005	18	166	40	206	125	720	185	<40	3
2006	17	161	41	202	109	650	179	<40	3
2007	16	218	40	258	155	660	235	<40	3
2008	15	263	60	323	199	630	291	<40	3
2009	14	278	64	342	190	650	305	<40	3
2010	13	251	64	315	179	690	282	<40	3
2011	12	306	67	373	211	690	331	<40	3
2012	11	256	62	318	179	710	291	<40	3
2013	10	244	61	305	162	700	257	<40	3
2014	9	264	43	307	160	730	261	<40	3
2015	9	254	42	296	156	705	258	<40	3
2016	7	229	48	277	154	700	245	<40	3
2017	7	193	32	225	130	660	199	<40	3
2018	6	173	45	218	121	750	196	<40	3

Definitions:

On treatment defined as being on ARV therapy in the specified month and not reported deceased

Duration defined as cumulative years on ARV therapy, excluding periods of treatment interruption

Current CD4 and PVL tests defined as tests done in the last 6 months (most recent)

Current ARV defined as number of ARV drugs in the current regimen





2.1 Duration of ARV treatment in the Province of BC, 1987-2024 (for HIV+ persons currently on treatment)

Start Year	Duration (years) Median	Male	Female	All	Current CD4 (n)	Current CD4 Median	Current PVL (n)	Current PVL Median	Current ARV Median
2019	5	210	40	250	158	630	228	<40	3
2020	4	162	55	217	142	735	192	<40	3
2021	3	184	35	219	132	635	201	<40	3
2022	2	243	49	292	189	700	269	<40	3
2023	1	284	69	353	268	555	337	<40	3
2024	0	49	17	66	61	550	62	<40	3
Total:		6326	1306	7632					

Definitions:

On treatment defined as being on ARV therapy in the specified month and not reported deceased

Duration defined as cumulative years on ARV therapy, excluding periods of treatment interruption

Current CD4 and PVL tests defined as tests done in the last 6 months (most recent)

Current ARV defined as number of ARV drugs in the current regimen





2.2 Median Viral Load and CD4 for Active patients in Drug Treatment Program

MON-YYYY	# of patients	Median # of therapy days	# of patients with PVL test	Median PVL	# of patients with CD4 test	Median CD4
JAN-2023	7581	793	2051	<40	1320	650
FEB-2023	7521	807	1727	<40	1020	630
MAR-2023	7548	803	1974	<40	1214	640
APR-2023	7553	796	1761	<40	1083	630
MAY-2023	7592	786	1933	<40	1234	650
JUN-2023	7599	787	1841	<40	1095	640
JUL-2023	7577	806	1747	<40	1053	620
AUG-2023	7600	806	1814	<40	1038	630
SEP-2023	7609	801	1775	<40	1059	650
OCT-2023	7611	804	1887	<40	1145	620
NOV-2023	7614	798	1854	<40	1084	650
DEC-2023	7609	801	1550	<40	898	648
JAN-2024	7651	792	1974	<40	1145	650
FEB-2024	7659	781	1777	<40	997	620

Definitions:

Active patient defined as being on ARV treatment in the specified month

Therapy days defined as number of consecutive days on ARV treatment (most recent uninterrupted period)

PVL and CD4 tests defined as tests done in the specified month





2.3 Median Viral Load and CD4 for Inactive patients in Drug Treatment Program

MON-YYYY	# of patients	Median # days of off therapy	# of patients with PVL test	Median PVL	# of patients with CD4 test	Median CD4
JAN-2023	734	276	63	<40	45	550
FEB-2023	787	230	66	<40	53	550
MAR-2023	756	242	78	<40	55	514
APR-2023	762	218	66	<40	47	560
MAY-2023	728	240	65	<40	48	430
JUN-2023	711	204	57	<40	39	460
JUL-2023	742	186	68	<40	50	565
AUG-2023	741	192	63	<40	40	595
SEP-2023	729	209	55	<40	41	540
OCT-2023	738	213	60	<40	46	625
NOV-2023	745	205	65	<40	46	515
DEC-2023	751	199	47	<40	35	473
JAN-2024	707	230	64	<40	46	530
FEB-2024	705	239	56	<40	38	605

Definitions:

Inactive patient defined as not deceased, not being on ARV treatment in the specified month (but previously treated with ARVs), and had contact with program in past 5 years

Days off therapy defined as number of days elapsed since last ARV treatment

PVL and CD4 tests defined as tests done in the specified month





2.4 BC-CfE Enrolment

MON-YYYY	Currently on ARV Therapy	Currently off ARV Therapy	Deceased	First Starts	Experienced Starts	New Inactive	Net Change	Cumulative Patients
JAN-2023	7550	734	20	10	193	143	40	14858
FEB-2023	7505	787	10	11	158	204	-45	14882
MAR-2023	7532	756	15	21	197	176	27	14916
APR-2023	7531	762	13	11	176	169	-1	14945
MAY-2023	7575	728	7	15	205	165	44	14989
JUN-2023	7578	711	14	17	168	165	3	15024
JUL-2023	7556	742	11	11	164	181	-22	15055
AUG-2023	7578	741	11	13	217	192	22	15100
SEP-2023	7579	729	14	5	179	164	1	15120
OCT-2023	7580	738	18	10	170	159	1	15151
NOV-2023	7580	745	17	9	183	172	0	15187
DEC-2023	7581	751	14	14	171	168	1	15221
JAN-2024	7621	707	16	11	204	158	40	15253
FEB-2024	7632	705	17	11	182	162	11	15287

Definitions:

Currently on ARV Therapy defined as being on ARV treatment in the specified month, and not deceased/moved out of BC

Currently off ARV Therapy defined as not being on ARV treatment in the specified month, not deceased/moved out of BC, but on ARVs in the past

Deceased defined as deceased in the specified month, and being on ARV treatment in the previous month

First Starts defined as starting ARV treatment in the specified month for the first time (ARV naive)

Experienced Starts defined as starting ARV treatment in the specified month, but previously being treated with ARVs

New Inactive defined as not being on ARV treatment in the specified month, not deceased/moved out of BC, but on ARV treatment in the previous month, and had contact with the program in the past 5 years

Net Change is defined as difference between ARV starts (First and Experienced) and ARV stops (Deceased/Moved out of BC and New Inactive)





2.5 Percent Distribution of Participants on ARV Therapy by Number of Drugs

MON-YYYY	Less than 3 Drugs	3 Drugs	4 Drugs	5 or more Drugs	All ARV	Less than 3 Drugs%	3 Drugs%	4 Drugs%	5 or more Drugs%	Total%
JAN-2023	721	6371	445	44	7581	9.51%	84.04%	5.87%	0.58%	100.00%
FEB-2023	735	6318	429	39	7521	9.77%	84.00%	5.70%	0.52%	100.00%
MAR-2023	750	6312	445	41	7548	9.94%	83.62%	5.90%	0.54%	100.00%
APR-2023	765	6307	440	41	7553	10.13%	83.50%	5.83%	0.54%	100.00%
MAY-2023	802	6314	435	41	7592	10.56%	83.17%	5.73%	0.54%	100.00%
JUN-2023	821	6299	438	41	7599	10.80%	82.89%	5.76%	0.54%	100.00%
JUL-2023	844	6253	440	40	7577	11.14%	82.53%	5.81%	0.53%	100.00%
AUG-2023	866	6240	448	46	7600	11.39%	82.11%	5.89%	0.61%	100.00%
SEP-2023	881	6250	432	46	7609	11.58%	82.14%	5.68%	0.60%	100.00%
OCT-2023	900	6237	433	41	7611	11.82%	81.95%	5.69%	0.54%	100.00%
NOV-2023	920	6212	441	41	7614	12.08%	81.59%	5.79%	0.54%	100.00%
DEC-2023	939	6196	434	40	7609	12.34%	81.43%	5.70%	0.53%	100.00%
JAN-2024	955	6221	433	42	7651	12.48%	81.31%	5.66%	0.55%	100.00%
FEB-2024	975	6208	437	39	7659	12.73%	81.05%	5.71%	0.51%	100.00%

Definitions:

Number of Drugs is calculated as number of individual drugs in ARV Therapy (excluding low dose ritonavir used for boosting a protease inhibitor)





2.6 Number of Participants on Nucleoside/Nucleotide Analogues by INGREDIENT

	lamivudine		abacavir		zidovudine		tenofovir <TAF>		tenofovir <TDF>		emtricitabine	
	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All
JAN-2023	6 17%	2971 40%	1 3%	2147 29%	1 3%	16 0%	23 66%	3491 47%	8 23%	1095 15%	29 83%	4465 60%
FEB-2023	3 13%	2944 40%	1 4%	2097 28%	0 0%	17 0%	18 75%	3502 47%	3 13%	1065 14%	21 88%	4446 60%
MAR-2023	2 6%	2936 40%	2 6%	2071 28%	0 0%	15 0%	27 79%	3551 48%	5 15%	1051 14%	32 94%	4476 60%
APR-2023	3 10%	2948 40%	1 3%	2067 28%	0 0%	15 0%	24 83%	3550 48%	3 10%	1030 14%	26 90%	4469 60%
MAY-2023	10 24%	2940 39%	4 10%	2043 27%	1 2%	16 0%	30 71%	3598 48%	3 7%	1040 14%	32 76%	4513 61%
JUN-2023	4 12%	2934 39%	1 3%	2008 27%	0 0%	14 0%	26 76%	3655 49%	4 12%	1002 13%	30 88%	4533 61%
JUL-2023	5 16%	2917 39%	1 3%	1966 26%	0 0%	14 0%	25 81%	3678 49%	2 6%	985 13%	26 84%	4530 61%
AUG-2023	4 9%	2909 39%	1 2%	1935 26%	0 0%	14 0%	34 76%	3717 50%	9 20%	969 13%	41 91%	4561 61%
SEP-2023	2 10%	2902 39%	1 5%	1910 26%	0 0%	13 0%	15 75%	3746 50%	3 15%	954 13%	18 90%	4578 61%
OCT-2023	2 6%	2904 39%	1 3%	1894 25%	0 0%	14 0%	23 74%	3766 50%	6 19%	936 13%	29 94%	4573 61%
NOV-2023	1 3%	2892 39%	0 0%	1866 25%	0 0%	15 0%	27 77%	3784 51%	7 20%	919 12%	34 97%	4586 61%
DEC-2023	6 18%	2877 39%	4 12%	1833 25%	0 0%	13 0%	26 76%	3823 51%	3 9%	896 12%	28 82%	4598 62%
JAN-2024	9 29%	2884 38%	8 26%	1833 24%	0 0%	13 0%	21 68%	3872 52%	2 6%	890 12%	22 71%	4639 62%
FEB-2024	8 24%	2871 38%	4 12%	1798 24%	0 0%	13 0%	23 68%	3904 52%	3 9%	864 11%	26 76%	4649 62%

Definitions:

Initial is defined as number of patients whose first ARV treatment with the BC-CfE DTP contains INGREDIENT;

% is calculated as ratio of "Initial" and number of patients whose first treatment is of given CLASS

All is defined as number of patients on ARV treatment which contains INGREDIENT;

% is calculated as ratio of "All" and number of patients whose treatment is of given CLASS





2.7 Number of Participants on Protease Inhibitor by INGREDIENT

	atazanavir		darunavir		lopinavir		ritonavir		tipranavir	
	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All
JAN-2023	0 0%	339 25%	1 100%	993 72%	0 0%	44 3%	0 0%	1 0%	0 0%	1 0%
FEB-2023	0 0%	321 24%	0 0%	953 73%	0 0%	43 3%	0 0%	1 0%	0 0%	1 0%
MAR-2023	0 0%	317 24%	1 100%	952 73%	0 0%	42 3%	0 0%	1 0%	0 0%	1 0%
APR-2023	0 0%	305 23%	1 100%	957 74%	0 0%	41 3%	0 0%	1 0%	0 0%	1 0%
MAY-2023	0 0%	303 23%	2 100%	951 74%	0 0%	39 3%	0 0%	1 0%	0 0%	1 0%
JUN-2023	0 0%	294 23%	0 0%	936 74%	0 0%	39 3%	0 0%	1 0%	0 0%	1 0%
JUL-2023	0 0%	283 23%	3 100%	927 74%	0 0%	38 3%	0 0%	1 0%	0 0%	1 0%
AUG-2023	0 0%	276 23%	3 100%	914 75%	0 0%	36 3%	0 0%	0 0%	0 0%	0 0%
SEP-2023	0 0%	271 22%	0 0%	909 75%	0 0%	35 3%	0 0%	0 0%	0 0%	0 0%
OCT-2023	1 50%	273 23%	1 50%	893 75%	0 0%	35 3%	0 0%	0 0%	0 0%	0 0%
NOV-2023	1 33%	260 22%	2 67%	890 75%	0 0%	35 3%	0 0%	0 0%	0 0%	0 0%
DEC-2023	0 0%	248 21%	1 100%	877 76%	0 0%	33 3%	0 0%	0 0%	0 0%	0 0%
JAN-2024	0 0%	241 21%	3 100%	869 76%	0 0%	33 3%	0 0%	0 0%	0 0%	0 0%
FEB-2024	0 0%	230 21%	0 0%	857 77%	0 0%	31 3%	0 0%	0 0%	0 0%	0 0%

Definitions:

Initial is defined as number of patients whose first ARV treatment with the BC-CfE DTP contains INGREDIENT;

% is calculated as ratio of "Initial" and number of patients whose first treatment is of given CLASS

All is defined as number of patients on ARV treatment which contains INGREDIENT;

% is calculated as ratio of "All" and number of patients whose treatment is of given CLASS

Ritonavir - greater than 400 mg total daily dose





2.8 Number of Participants on Non-Nucleosides by INGREDIENT

	doravirine		efavirenz		etravirine		nevirapine		rilpivirine	
	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All
JAN-2023	3 43%	192 19%	4 57%	247 25%	0 0%	107 11%	0 0%	255 26%	0 0%	191 19%
FEB-2023	0 0%	202 20%	0 0%	250 25%	0 0%	98 10%	0 0%	249 25%	0 0%	190 19%
MAR-2023	0 0%	209 21%	0 0%	242 25%	0 0%	101 10%	0 0%	246 25%	0 0%	186 19%
APR-2023	1 50%	215 22%	1 50%	232 24%	0 0%	96 10%	0 0%	245 25%	0 0%	187 19%
MAY-2023	1 33%	223 23%	0 0%	232 24%	0 0%	98 10%	0 0%	239 24%	2 67%	187 19%
JUN-2023	0 0%	224 23%	3 75%	228 24%	0 0%	96 10%	0 0%	230 24%	1 25%	180 19%
JUL-2023	0 0%	235 25%	1 100%	222 23%	0 0%	94 10%	0 0%	225 24%	0 0%	178 19%
AUG-2023	0 0%	238 25%	2 100%	222 23%	0 0%	91 10%	0 0%	223 23%	0 0%	182 19%
SEP-2023	0 0%	236 25%	0 0%	218 23%	0 0%	88 9%	1 100%	220 23%	0 0%	177 19%
OCT-2023	0 0%	239 26%	2 100%	216 23%	0 0%	89 10%	0 0%	220 24%	0 0%	173 19%
NOV-2023	0 0%	243 26%	0 0%	209 22%	1 50%	88 9%	0 0%	219 24%	1 50%	173 19%
DEC-2023	1 50%	251 27%	0 0%	205 22%	0 0%	87 9%	0 0%	213 23%	1 50%	176 19%
JAN-2024	0 0%	250 27%	0 0%	200 22%	0 0%	83 9%	0 0%	208 23%	2 100%	181 20%
FEB-2024	0 0%	256 28%	0 0%	192 21%	0 0%	82 9%	0 0%	207 23%	0 0%	182 20%

Definitions:

Initial is defined as number of patients whose first ARV treatment with the BC-CfE DTP contains INGREDIENT;

% is calculated as ratio of "Initial" and number of patients whose first treatment is of given CLASS

All is defined as number of patients on ARV treatment which contains INGREDIENT;

% is calculated as ratio of "All" and number of patients whose treatment is of given CLASS

Doravirine not currently available on BC-CfE Formulary





2.9 Number of Participants on Entry/Integrase Inhibitors by INGREDIENT

	bictegravir		cabotegravir		dolutegravir		elvitegravir		fostemsavir		maraviroc		raltegravir	
	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All
JAN-2023	23 82%	3016 50%	0 0%	0 0%	5 18%	2492 41%	0 0%	269 4%	0 0%	2 0%	0 0%	21 0%	0 0%	302 5%
FEB-2023	18 75%	3040 50%	0 0%	0 0%	6 25%	2476 41%	0 0%	255 4%	0 0%	2 0%	0 0%	21 0%	0 0%	288 5%
MAR-2023	25 74%	3084 51%	0 0%	0 0%	5 15%	2482 41%	2 6%	259 4%	0 0%	2 0%	0 0%	20 0%	2 6%	291 5%
APR-2023	22 81%	3084 50%	0 0%	0 0%	4 15%	2498 41%	1 4%	258 4%	0 0%	2 0%	0 0%	18 0%	0 0%	274 4%
MAY-2023	28 67%	3138 51%	1 2%	3 0%	12 29%	2504 41%	1 2%	250 4%	0 0%	2 0%	0 0%	18 0%	0 0%	278 5%
JUN-2023	26 81%	3197 51%	0 0%	5 0%	6 19%	2509 40%	0 0%	248 4%	0 0%	2 0%	0 0%	18 0%	0 0%	267 4%
JUL-2023	25 83%	3218 52%	0 0%	5 0%	5 17%	2499 40%	0 0%	247 4%	0 0%	2 0%	0 0%	18 0%	0 0%	256 4%
AUG-2023	33 79%	3258 52%	0 0%	7 0%	6 14%	2495 40%	1 2%	245 4%	0 0%	2 0%	0 0%	18 0%	2 5%	253 4%
SEP-2023	15 79%	3289 52%	0 0%	8 0%	4 21%	2500 40%	0 0%	238 4%	0 0%	2 0%	0 0%	18 0%	0 0%	249 4%
OCT-2023	22 76%	3298 52%	0 0%	7 0%	7 24%	2523 40%	0 0%	241 4%	0 0%	2 0%	0 0%	18 0%	0 0%	248 4%
NOV-2023	27 82%	3328 53%	0 0%	9 0%	6 18%	2518 40%	0 0%	233 4%	0 0%	1 0%	0 0%	17 0%	0 0%	244 4%
DEC-2023	25 78%	3368 53%	0 0%	13 0%	7 22%	2507 40%	0 0%	226 4%	0 0%	2 0%	0 0%	16 0%	0 0%	237 4%
JAN-2024	20 65%	3423 53%	1 3%	16 0%	10 32%	2522 39%	0 0%	225 4%	0 0%	2 0%	0 0%	18 0%	0 0%	233 4%
FEB-2024	22 65%	3459 54%	0 0%	15 0%	11 32%	2519 39%	0 0%	219 3%	0 0%	2 0%	0 0%	18 0%	1 3%	230 4%

Definitions:

Initial is defined as number of patients whose first ARV treatment with the BC-CfE DTP contains INGREDIENT;

% is calculated as ratio of "Initial" and number of patients whose first treatment is of given CLASS

All is defined as number of patients on ARV treatment which contains INGREDIENT;

% is calculated as ratio of "All" and number of patients whose treatment is of given CLASS

Fostemsavir not currently on BC-CfE Formulary





2.10 Distribution of Participants in HIV/AIDS Drug Treatment Program by Regimen Category

MON-YYYY	Boosted PI + 2 N(t)RTIs		NNRTI + 2 N(t)RTIs		INSTI + 2 N(t)RTIs		2 drugs from 2 classes		3 drugs from 3 classes		Other	
	n	%	n	%	n	%	n	%	n	%	n	%
JAN-2023	750	9.89	665	8.77	4728	62.37	718	9.47	649	8.56	71	0.94
FEB-2023	715	9.51	665	8.84	4712	62.65	733	9.75	626	8.32	70	0.93
MAR-2023	699	9.26	653	8.65	4735	62.73	748	9.91	644	8.53	69	0.91
APR-2023	704	9.32	653	8.65	4736	62.70	762	10.09	634	8.39	64	0.85
MAY-2023	706	9.30	644	8.48	4752	62.59	800	10.54	627	8.26	63	0.83
JUN-2023	675	8.88	625	8.22	4788	63.01	819	10.78	627	8.25	65	0.86
JUL-2023	662	8.74	626	8.26	4758	62.80	842	11.11	628	8.29	61	0.81
AUG-2023	643	8.46	621	8.17	4773	62.80	864	11.37	632	8.32	67	0.88
SEP-2023	639	8.40	616	8.10	4793	62.99	879	11.55	617	8.11	65	0.85
OCT-2023	614	8.07	612	8.04	4808	63.17	897	11.79	618	8.12	62	0.81
NOV-2023	611	8.02	600	7.88	4800	63.04	918	12.06	624	8.20	61	0.80
DEC-2023	594	7.81	597	7.85	4811	63.23	937	12.31	614	8.07	56	0.74
JAN-2024	585	7.65	585	7.65	4861	63.53	953	12.46	610	7.97	57	0.75
FEB-2024	568	7.42	585	7.64	4867	63.55	972	12.69	610	7.96	57	0.74

Definitions:

n is number of participants on the specified regimen class in the specified month

% is ratio of n and total number of participants on ART in the specified month

Regimen categories may contain a small number of participants with undetermined regimen, due to medication change(s) within the month





2.11 Baseline CD4 for Antiretroviral First Starts

MON-YYYY	# of First Starts	# of Pts with CD4 < 100	# of Pts with CD4: 100-199	# of Pts with CD4: 200-349	# of Pts with CD4: 350-500	# of Pts with CD4 > 500	Median CD4
JAN-2023	10	2	2	2	2	2	285
FEB-2023	11	2	2	3	1	3	253
MAR-2023	21	0	0	4	3	11	530
APR-2023	11	1	3	1	1	4	325
MAY-2023	15	2	1	2	5	2	374
JUN-2023	17	2	4	3	2	6	340
JUL-2023	11	1	2	3	2	3	260
AUG-2023	13	2	1	4	1	2	252
SEP-2023	5	1	1	0	0	3	616
OCT-2023	10	0	1	3	2	3	390
NOV-2023	9	1	1	0	2	4	575
DEC-2023	14	1	0	3	0	9	593
JAN-2024	11	2	2	2	1	3	287
FEB-2024	11	1	2	4	2	1	281

Definitions:

First Starts defined as starting ARV treatment in the specified month for the first time (ARV naive)

Baseline CD4 is defined as most recent CD4 test before ARV start





2.12 DTP Participants with PVL Measurement within previous five years, and never on ART

MON-YYYY	# of Participants with PVL test	# of Participants with PVL test, and never on ART
JAN-2023	12448	3803
FEB-2023	12436	3788
MAR-2023	12443	3787
APR-2023	12418	3753
MAY-2023	12426	3731
JUN-2023	12399	3693
JUL-2023	12426	3716
AUG-2023	12423	3698
SEP-2023	12410	3686
OCT-2023	12394	3662
NOV-2023	12381	3649
DEC-2023	12402	3656
JAN-2024	12411	3664
FEB-2024	12424	3669

Definitions:


Patients with PVL test are defined as having at least one PVL test within previous five years, and not reported deceased/moved
Never on ART are subset of patients with PVL test, and not being treated with ARVs on or before specified month






3.1 Distribution of HIV/AIDS Drug Treatment Program Active Participants Feb-2024 N = 7659

BY HEALTH SERVICES DELIVERY AREA




BY HEALTH AUTHORITY






3.2 Distribution of HIV/AIDS Drug Treatment Program Active Participant
Feb-2024

INTERIOR HEALTH AUTHORITY BY HEALTH SERVICES DELIVERY AREA/LOCAL HEALTH AREA




KELOWNA BY POSTAL CODE






3.3 Distribution of HIV/AIDS Drug Treatment Program Active Participant
Feb-2024

FRASER HEALTH AUTHORITY BY HEALTH SERVICES DELIVERY AREA/LOCAL HEALTH AREA




SURREY BY POSTAL CODE






3.4 Distribution of HIV/AIDS Drug Treatment Program Active Participant
Feb-2024

VANCOUVER COASTAL HEALTH AUTHORITY BY HEALTH SERVICES DELIVERY AREA/LOCAL HEALTH AREA




VANCOUVER BY POSTAL CODE






3.5 Distribution of HIV/AIDS Drug Treatment Program Active Participant
Feb-2024

VANCOUVER ISLAND HEALTH AUTHORITY BY HEALTH SERVICES DELIVERY AREA/LOCAL HEALTH AREA




VICTORIA BY POSTAL CODE






3.6 Distribution of HIV/AIDS Drug Treatment Program Active Participant
Feb-2024

NORTHERN HEALTH AUTHORITY BY HEALTH SERVICES DELIVERY AREA/LOCAL HEALTH AREA



PRINCE GEORGE BY POSTAL CODE





4.1 Distribution of Participants in BC-CfE Registries by Age and Sex at Birth INTERIOR Health Authority

HSDA	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
EAST KOOTENAY	20-34	5	5	*
	35-49	14	14	*
	50+	27	43	*
	Total HSDA:	46	62	28
KOOTENAY BOUNDARY	0-19	*	*	*
	20-34	*	*	*
	35-49	*	*	*
	50+	*	*	*
Total HSDA:	70	100	48	
OKANAGAN	0-19	*	*	0
	20-34	*	*	28
	35-49	*	*	84
	50+	*	*	222
Total HSDA:	454	615	334	
THOMPSON/CARIBOO/ SHUSWAP	0-19	*	*	*
	20-34	*	*	*
	35-49	*	*	*
	50+	*	*	*
Total HSDA:	234	321	174	
Total HA:		804	1098	584

	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
	0-19	6	6	*
	20-34	78	79	*
	35-49	189	207	*
	50+	531	806	*
Total HA:		804	1098	584

Sex at Birth	Alive	Ever treated with ARVs	Currently treated with ARVs
Female	162	225	117
Male	642	873	467

Currently treated with ARVs	# of patients	Med Age	Med CD4	Med PVL
Total HA:	584	56	660	<40

* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Med CD4 and PVL tests defined as most recent tests (as of specified month)





4.2 Distribution of Participants in BC-CfE Registries by Treatment Duration INTERIOR Health Authority

HSDA	Treatment Duration	Alive	Currently treated with ARVs
EAST KOOTENAY	10 years or more	24	14
	5 years or more	15	9
	<5 years	7	5
	Total HSDA:	46	28
KOOTENAY BOUNDARY	10 years or more	47	30
	5 years or more	13	10
	<5 years	10	8
	Total HSDA:	70	48
OKANAGAN	10 years or more	291	209
	5 years or more	84	58
	<5 years	79	67
	Total HSDA:	454	334
THOMPSON/CARIBOO/ SHUSWAP	10 years or more	144	108
	5 years or more	41	27
	<5 years	49	39
	Total HSDA:	234	174
Total HA:		804	584

	Treatment Duration	Alive	Currently treated with ARVs
	10 years or more	506	361
	5 years or more	153	104
	<5 years	145	119
Total HA:		804	584

* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Treatment Duration defined as number of years since ARV initiation





4.3 Distribution of ARV Prescribers in BC-CfE Registries INTERIOR Health Authority

HSDA of Prescriber Residency	# of Prescribers ever prescribed ARVs	# of Patients ever treated by Prescribers	# of Prescribers currently prescribing ARVs	# of Patients currently treated by Prescribers
EAST KOOTENAY	54	96	12	26
KOOTENAY BOUNDARY	76	138	19	42
OKANAGAN	241	1069	53	310
THOMPSON/CARIBOO/SHUSWAP	151	578	33	142
Total:	522	1881	117	520

HSDA of Patient Residency	# of Patients seeking Prescriber's care out of HA
EAST KOOTENAY	*
KOOTENAY BOUNDARY	*
OKANAGAN	*
THOMPSON/CARIBOO/SHUSWAP	*
Total:	131

* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently prescribing/treated defined as prescribing/being treated in the previous 6 months

of Patients seeking Prescriber out of HA is defined as patients residing in specified HSDA, but their follow-up prescriber(s) reside in another HA





4.4 Distribution of Participants in BC-CfE Registries by Age and Sex at Birth FRASER Health Authority

HSDA	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
FRASER EAST	0-19	7	7	6
	20-34	46	48	37
	35-49	102	105	70
	50+	274	383	202
	Total HSDA:	429	543	315
FRASER NORTH	20-34	148	149	105
	35-49	356	386	277
	50+	653	1040	495
	Total HSDA:	1157	1575	877
FRASER SOUTH	0-19	8	8	5
	20-34	121	124	91
	35-49	307	335	241
	50+	637	980	507
	Total HSDA:	1073	1447	844
Total HA:		2659	3565	2036

	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
	0-19	15	15	11
	20-34	315	321	233
	35-49	765	826	588
	50+	1564	2403	1204
Total HA:		2659	3565	2036

Sex at Birth	Alive	Ever treated with ARVs	Currently treated with ARVs
Female	646	830	485
Male	2013	2735	1551

Currently treated with ARVs	# of patients	Med Age	Med CD4	Med PVL
Total HA:	2036	53	650	<40

* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Med CD4 and PVL tests defined as most recent tests (as of specified month)





**4.5 Distribution of Participants in BC-CfE Registries by Treatment Duration
FRASER Health Authority**

HSDA	Treatment Duration	Alive	Currently treated with ARVs
FRASER EAST	10 years or more	283	209
	5 years or more	73	44
	<5 years	73	62
	Total HSDA:	429	315
FRASER NORTH	10 years or more	735	535
	5 years or more	226	175
	<5 years	196	167
	Total HSDA:	1157	877
FRASER SOUTH	10 years or more	658	506
	5 years or more	214	165
	<5 years	201	173
	Total HSDA:	1073	844
Total HA:		2659	2036

	Treatment Duration	Alive	Currently treated with ARVs
	10 years or more	1676	1250
	5 years or more	513	384
	<5 years	470	402
Total HA:		2659	2036

* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Treatment Duration defined as number of years since ARV initiation





4.6 Distribution of ARV Prescribers in BC-CfE Registries FRASER Health Authority

HSDA of Prescriber Residency	# of Prescribers ever prescribed ARVs	# of Patients ever treated by Prescribers	# of Prescribers currently prescribing ARVs	# of Patients currently treated by Prescribers
FRASER EAST	151	553	32	61
FRASER NORTH	266	1656	43	228
FRASER SOUTH	231	1855	44	489
Total:	648	4064	119	778

HSDA of Patient Residency	# of Patients seeking Prescriber's care out of HA
FRASER EAST	208
FRASER NORTH	723
FRASER SOUTH	477
Total:	1408

* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently prescribing/treated defined as prescribing/being treated in the previous 6 months

of Patients seeking Prescriber out of HA is defined as patients residing in specified HSDA, but their follow-up prescriber(s) reside in another HA





**4.7 Distribution of Participants in BC-CfE Registries by Age and Sex at Birth
VANCOUVER COASTAL Health Authority**

HSDA	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
NORTH SHORE/ COAST GARIBALDI	0-19	*	*	*
	20-34	*	*	*
	35-49	*	*	*
	50+	*	*	*
	Total HSDA:		368	542
RICHMOND	20-34	33	34	23
	35-49	60	61	49
	50+	125	182	99
	Total HSDA:	218	277	171
VANCOUVER	0-19	9	9	7
	20-34	442	458	305
	35-49	1208	1352	840
	50+	3010	5433	2153
	Total HSDA:	4669	7252	3305
Total HA:		5255	8071	3758

	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
	0-19	13	13	11
	20-34	504	521	346
	35-49	1343	1495	941
	50+	3395	6042	2460
Total HA:		5255	8071	3758

Sex at Birth	Alive	Ever treated with ARVs	Currently treated with ARVs
Female	601	986	456
Male	4652	7083	3302
Unknown	2	2	0

Currently treated with ARVs	# of patients	Med Age	Med CD4	Med PVL
Total HA:	3758	56	660	<40

* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Med CD4 and PVL tests defined as most recent tests (as of specified month)





4.8 Distribution of Participants in BC-CfE Registries by Treatment Duration VANCOUVER COASTAL Health Authority

HSDA	Treatment Duration	Alive	Currently treated with ARVs
NORTH SHORE/ COAST GARIBALDI	10 years or more	253	194
	5 years or more	55	45
	<5 years	60	43
	Total HSDA:	368	282
RICHMOND	10 years or more	128	97
	5 years or more	33	24
	<5 years	57	50
	Total HSDA:	218	171
VANCOUVER	10 years or more	3318	2282
	5 years or more	743	531
	<5 years	608	492
	Total HSDA:	4669	3305
Total HA:		5255	3758

	Treatment Duration	Alive	Currently treated with ARVs
	10 years or more	3699	2573
	5 years or more	831	600
	<5 years	725	585
Total HA:		5255	3758

* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Treatment Duration defined as number of years since ARV initiation





**4.9 Distribution of ARV Prescribers in BC-CfE Registries
VANCOUVER COASTAL Health Authority**

HSDA of Prescriber Residency	# of Prescribers ever prescribed ARVs	# of Patients ever treated by Prescribers	# of Prescribers currently prescribing ARVs	# of Patients currently treated by Prescribers
NORTH SHORE/COAST GARIBALDI	191	418	36	52
RICHMOND	47	325	9	102
VANCOUVER	704	11897	217	5478
Total:	942	12640	262	5632

HSDA of Patient Residency	# of Patients seeking Prescriber's care out of HA
NORTH SHORE/COAST GARIBALDI	15
RICHMOND	5
VANCOUVER	47
Total:	67

* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently prescribing/treated defined as prescribing/being treated in the previous 6 months

of Patients seeking Prescriber out of HA is defined as patients residing in specified HSDA, but their follow-up prescriber(s) reside in another HA





**4.10 Distribution of Participants in BC-CfE Registries by Age and Sex at Birth
VANCOUVER ISLAND Health Authority**

HSDA	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
CENTRAL VANCOUVER ISLAND	0-19	*	*	*
	20-34	*	*	*
	35-49	*	*	*
	50+	*	*	*
	Total HSDA:		360	530
NORTH VANCOUVER ISLAND	0-19	*	*	*
	20-34	*	*	*
	35-49	*	*	*
	50+	*	*	*
	Total HSDA:		134	189
SOUTH VANCOUVER ISLAND	0-19	*	*	*
	20-34	*	*	*
	35-49	*	*	*
	50+	*	*	*
	Total HSDA:		830	1190
Total HA:		1324	1909	1014

	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
	0-19	6	6	6
	20-34	111	120	68
	35-49	303	342	227
	50+	904	1441	713
Total HA:		1324	1909	1014

Sex at Birth	Alive	Ever treated with ARVs	Currently treated with ARVs
Female	222	324	168
Male	1102	1585	846

Currently treated with ARVs	# of patients	Med Age	Med CD4	Med PVL
Total HA:	1014	57	610	<40

* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Med CD4 and PVL tests defined as most recent tests (as of specified month)





4.11 Distribution of Participants in BC-CfE Registries by Treatment Duration VANCOUVER ISLAND Health Authority

HSDA	Treatment Duration	Alive	Currently treated with ARVs
CENTRAL VANCOUVER ISLAND	10 years or more	235	190
	5 years or more	64	43
	<5 years	61	48
	Total HSDA:	360	281
NORTH VANCOUVER ISLAND	10 years or more	97	77
	5 years or more	24	19
	<5 years	13	12
	Total HSDA:	134	108
SOUTH VANCOUVER ISLAND	10 years or more	517	381
	5 years or more	157	117
	<5 years	156	127
	Total HSDA:	830	625
Total HA:		1324	1014

	Treatment Duration	Alive	Currently treated with ARVs
	10 years or more	849	648
	5 years or more	245	179
	<5 years	230	187
Total HA:		1324	1014

* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Treatment Duration defined as number of years since ARV initiation





**4.12 Distribution of ARV Prescribers in BC-CfE Registries
VANCOUVER ISLAND Health Authority**

HSDA of Prescriber Residency	# of Prescribers ever prescribed ARVs	# of Patients ever treated by Prescribers	# of Prescribers currently prescribing ARVs	# of Patients currently treated by Prescribers
CENTRAL VANCOUVER ISLAND	206	944	67	197
NORTH VANCOUVER ISLAND	161	288	37	67
SOUTH VANCOUVER ISLAND	231	1994	40	598
Total:	598	3226	144	862

HSDA of Patient Residency	# of Patients seeking Prescriber's care out of HA
CENTRAL VANCOUVER ISLAND	77
NORTH VANCOUVER ISLAND	48
SOUTH VANCOUVER ISLAND	128
Total:	253

* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently prescribing/treated defined as prescribing/being treated in the previous 6 months

of Patients seeking Prescriber out of HA is defined as patients residing in specified HSDA, but their follow-up prescriber(s) reside in another HA





**4.13 Distribution of Participants in BC-CfE Registries by Age and Sex at Birth
NORTHERN Health Authority**

HSDA	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
NORTH EAST	20-34	9	9	6
	35-49	18	21	12
	50+	29	39	15
	Total HSDA:	56	69	33
NORTH WEST	20-34	*	5	*
	35-49	*	36	*
	50+	*	82	*
	Total HSDA:	75	123	59
NORTHERN INTERIOR	0-19	*	*	*
	20-34	*	*	*
	35-49	*	*	*
	50+	*	*	*
	Total HSDA:	206	307	156
Total HA:		337	499	248

	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
	0-19	*	*	*
	20-34	*	*	*
	35-49	*	*	*
	50+	*	*	*
Total HA:		337	499	248

Sex at Birth	Alive	Ever treated with ARVs	Currently treated with ARVs
Female	117	178	85
Male	220	321	163

Currently treated with ARVs	# of patients	Med Age	Med CD4	Med PVL
Total HA:	248	53	570	<40

* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Med CD4 and PVL tests defined as most recent tests (as of specified month)





**4.14 Distribution of Participants in BC-CfE Registries by Treatment Duration
NORTHERN Health Authority**

HSDA	Treatment Duration	Alive	Currently treated with ARVs
NORTH EAST	10 years or more	31	*
	5 years or more	8	*
	<5 years	17	*
	Total HSDA:	56	33
NORTH WEST	10 years or more	53	41
	5 years or more	11	8
	<5 years	11	10
	Total HSDA:	75	59
NORTHERN INTERIOR	10 years or more	121	91
	5 years or more	48	34
	<5 years	37	31
	Total HSDA:	206	156
Total HA:		337	248

	Treatment Duration	Alive	Currently treated with ARVs
	10 years or more	205	147
	5 years or more	67	45
	<5 years	65	56
Total HA:		337	248

* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Treatment Duration defined as number of years since ARV initiation





**4.15 Distribution of ARV Prescribers in BC-CfE Registries
NORTHERN Health Authority**

HSDA of Prescriber Residency	# of Prescribers ever prescribed ARVs	# of Patients ever treated by Prescribers	# of Prescribers currently prescribing ARVs	# of Patients currently treated by Prescribers
NORTH EAST	39	51	5	7
NORTH WEST	89	168	14	32
NORTHERN INTERIOR	126	511	25	196
Total:	254	730	44	235

HSDA of Patient Residency	# of Patients seeking Prescriber's care out of HA
NORTH EAST	7
NORTH WEST	22
NORTHERN INTERIOR	18
Total:	47

* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently prescribing/treated defined as prescribing/being treated in the previous 6 months

of Patients seeking Prescriber out of HA is defined as patients residing in specified HSDA, but their follow-up prescriber(s) reside in another HA





4.16 Distribution of Indigenous Participants in BC-CfE Registries by Health Service Delivery Area and Sex at Birth

HA	HSDA	Alive	Ever treated with ARVs	Currently treated with ARVs
INTERIOR	EAST KOOTENAY	*	10	*
	KOOTENAY BOUNDARY	*	9	*
	OKANAGAN	*	52	*
	THOMPSON/CARIBOO/SHUSWAP	*	54	*
	Total HA:	68	125	46
FRASER	FRASER EAST	37	53	29
	FRASER NORTH	52	96	42
	FRASER SOUTH	77	116	53
	Total HA:	166	265	124
VANCOUVER COASTAL	NORTH SHORE/COAST GARIBALDI	28	55	25
	RICHMOND	7	12	5
	VANCOUVER	440	915	360
	Total HA:	475	982	390
VANCOUVER ISLAND	CENTRAL VANCOUVER ISLAND	49	85	37
	NORTH VANCOUVER ISLAND	15	30	11
	SOUTH VANCOUVER ISLAND	48	96	38
	Total HA:	112	211	86
NORTHERN	NORTH EAST	12	16	9
	NORTH WEST	33	69	26
	NORTHERN INTERIOR	73	122	62
	Total HA:	118	207	97
Total:		939	1790	743

Sex at Birth	Alive	Ever treated with ARVs	Currently treated with ARVs
Male	600	1152	462
Female	339	638	281

Currently treated with ARVs	# of patients	Med Age	Med CD4	Med PVL
Total:	743	54	530	<40

* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Med CD4 and PVL tests defined as most recent tests (as of specified month)





5.1 Drug Names and Definitions

Abacavir: a NUCLEOSIDE ANALOG from ViiV Healthcare.

Active: persons in the HIV/AIDS Drug Treatment program that are prescribed one or more drugs in this current month

Antiretroviral: a substance that stops or suppresses the activity of a retrovirus, such as HIV. NUCLEOSIDE ANALOGS and PROTEASE INHIBITORS are examples of antiretroviral drugs.

Atazanavir (Reyataz): a PROTEASE INHIBITOR from Bristol-Myers Squibb.

Atovaquone (Mepron): a medication used to treat pneumocystis carinii pneumonia and, in some cases, toxoplasmosis.

Atripla: the Bristol-Myers Squibb and Gilead trade name for a tablet containing EFAVIRENZ, TENOFOVIR DF and EMTRICITABINE.

Azithromycin (Zithromax): an antibiotic used for the prevention of mycobacterium avium complex (MAC) in people with advanced HIV infection.

Bictegravir: an INTEGRASE INHIBITOR from Gilead Sciences.

Boosted PI: a PI and a small (400 mg or less, total daily dose) additional dose or RITONAVIR. The addition of RITONAVIR inhibits metabolism of other PIs and improves their exposure. This may allow for decreased dosing frequency or pill burden and may improve adherence and antiretroviral activity.

Cabenuva: the ViiV Healthcare trade name for an injectable formulation containing CABOTEGRAVIR and RILPIVIRINE.

Cabotegravir: an INTEGRASE INHIBITOR.

CD4 Cell Count: the most commonly used marker for assessing the state of the immune system. As CD4 cell count declines, the risk of developing opportunistic infections increases. Normal CD4 cell counts are greater than 800 per cubic millimeter of blood.

Chemokine Receptor Inhibitor: a type of ENTRY INHIBITOR designed to prevent HIV entry by blocking the binding site of co-receptors, such as CCR5 or CXCR4.

Clarithromycin (Biaxin): an antibiotic used for the treatment of mycobacterium avium complex (MAC). It is also used for preventing MAC in those with advanced HIV infection.

Cobicistat: a pharmacokinetic enhancer (“booster”) given with other antiretrovirals to improve drug exposure. Cobicistat has no anti-HIV activity. It is currently available as a component of STRIBILD, GENVOYA and PREZCOBIX.

Combination Therapy: initial combination therapy for HIV contains at least three ANTIRETROVIRALS.

Complera: the Gilead trade name for a tablet containing EMTRICITABINE, RILPIVIRINE and TENOFOVIR DF.

Darunavir (Prezista): a PROTEASE INHIBITOR from Janssen that has activity against HIV in treatment-experienced patients.

Deceased: persons enrolled in the HIV/AIDS Drug Treatment program that died in this time period.

Descovy: the Gilead trade name for a tablet containing EMTRICITABINE and TENOFOVIR AF.





Monthly Report

Didanosine (Videx): a NUCLEOSIDE ANALOG from Bristol-Myers Squibb.

Dolutegravir (Tivicay): an INTEGRASE INHIBITOR from ViiV Healthcare.

Doravirine: a NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR (NNRTI) from Merck.

Efavirenz (Sustiva, Auro efavirenz): a NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR (NNRTI) from Bristol-Myers Squibb.

Elvitegravir: an INTEGRASE INHIBITOR from Gilead Sciences. It is currently available as a component of STRIBILD.

Emtricitabine: a NUCLEOSIDE ANALOG from Gilead Sciences. It is currently available as a component of TRUVADA and other combinations.

Enfuvirtide (Fuzeon): a FUSION INHIBITOR from Hoffman-La Roche that targets the gp41 protein on the surface of HIV. It is administered as a subcutaneous injection.

Entry Inhibitor: a drug that inhibits the entry of HIV into cells. Entry inhibitors include FUSION INHIBITORS, CHEMOKINE RECEPTOR INHIBITORS, and attachment inhibitors.

Etravirine (Intence): a NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR from Janssen that has activity against HIV in treatment-experienced patients.

First started program: a person prescribed their first regimen ever in the HIV/AIDS drug treatment program.

Fosamprenavir (Telzir): a PROTEASE INHIBITOR from ViiV Healthcare. Fosamprenavir is a PRODRUG of AMPRENAVIR.

Fostemsavir: an ATTACHMENT INHIBITOR from ViiV Healthcare. Fostemsavir is a PRODRUG of TEMSAVIR.

Fusion Inhibitor: a type of ENTRY INHIBITOR designed to prevent HIV from fusing with and thereby infecting CD4 cells.

Genvoya: the Gilead trade name for a tablet containing ELVITEGRAVIR, COBICSTAT, EMTRICITABINE and TENOFOVIR AF.

Health Authority: refers to the five (Interior, Fraser, Northern, Vancouver Coastal, Vancouver Island) health authorities created by the BC Ministry of Health.

Inactive: persons no longer dispensed drugs through the HIV/AIDS Drug Treatment program this current month.

Integrase Inhibitor: a drug that blocks integrase, a protein that HIV needs to enter cells and produce copies of itself, from working.

Kivexa: the ViiV Healthcare's trade name for a tablet containing both ABACAVIR and LAMIVUDINE.

Lamivudine: a NUCLEOSIDE ANALOG from ViiV Healthcare with activity against HIV and hepatitis B.

Lopinavir (Kaletra): a PROTEASE INHIBITOR from Abbott Laboratories. Kaletra is a combination of lopinavir and a low dose of RITONAVIR, a drug that improves blood levels of lopinavir.

Maraviroc (Celsentri): a CHEMOKINE RECEPTOR INHIBITOR from ViiV Healthcare that inhibits HIV entry by blocking the binding site of the CCR5 co-receptor.

Median (MED) age: median age of participants in the HIV/AIDS Drug Treatment program in that time period.





MDRT: see MULTIPLE DRUG RESCUE THERAPY

Moved out of BC: a person in the HIV/AIDS Drug Treatment program that is no longer in the program, because they moved out of BC in this time period.

Multiple Drug Rescue Therapy (MDRT or Mega-HAART): the use of five or more antiretrovirals to treat HIV, typically some or all of which have been used previously by the individual.

Nelfinavir (Viracept): a PROTEASE INHIBITOR from ViiV Healthcare.

Net change: the net increase or decrease in persons enrolled in the HIV/AIDS Drug Treatment Program from the previous time period.

Nevirapine (Viramune): a NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR (NNRTI) from Boehringer Ingelheim.

NNRTI: see NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR.

NNRTI / no PI: a combination therapy regimen of four or fewer antiretroviral drugs, including an NNRTI, but no PIs.

Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI): a member of a class of compounds, including DELAVIRDINE, NEVIRAPINE, EFAVIRENZ and ETRAVIRINE that acts to directly combine with and block the action of HIV's reverse transcriptase enzyme.

N(t)RTI: a category of drug encompassing both NUCLEOSIDE ANALOG and NUCLEOTIDE ANALOG

Nucleoside Analog (Nucleoside Analog Reverse Transcriptase Inhibitor, NRTI): a type of ANTIVIRAL drug whose structure constitutes a defective version of a natural nucleoside. Nucleoside analogs may take the place of the natural nucleosides, blocking the completion of a viral DNA chain during infection of a new cell by HIV. The HIV enzyme reverse transcriptase is more likely to incorporate nucleoside analogs into the DNA it is constructing than is the DNA polymerase that cells normally use for DNA construction.

Nucleotide Analog: ANTIVIRAL compounds that function exactly like NUCLEOSIDE ANALOGS but are pre-activated through the addition of a phosphate group during their synthesis. This phosphorylation is supposed to enhance the drug levels and activity achieved within cells.

Odefsey: the Gilead trade name for a tablet containing RILPIVIRINE, EMTRICITABINE and TENOFOVIR AF.

One or more PI: a combination therapy regimen of four or fewer antiretroviral drugs, including one unboosted PI or 2 or more PIs with or without a small (400 mg or less, total daily dose) additional dose of RITONAVIR.

Other: an antiretroviral regimen in the HIV/AIDS Drug Treatment program other than NNRTI/no PI, boosted PI, 1 or more PIs or MDRT-based regimens (eg. Triple Nucleoside regimens).

Pentamidine: an antiprotozoal drug used in aerosol form as a preventative against pneumocystis carinii pneumonia (PCP).

PI: see PROTEASE INHIBITOR.

Prezcobix: the Janssen trade name for a tablet containing DARUNAVIR and COBICISTAT.

Prodrug: a compound that is converted within the body into the active form that has medical effects.

Protease Inhibitor: a drug that binds to and blocks HIV protease from working, thus preventing the production of new functional viral particles.





Monthly Report

Raltegravir (Isentress): an INTEGRASE INHIBITOR from Merck.

Restarted/ changed therapy (Tx): a person in the HIV/AIDS Drug Treatment program that was either CURRENTLY OFF THERAPY and now has been prescribed a new regimen or a person who has changed regimens.

Rifabutin (Mycobutin): an oral drug used to prevent mycobacterium avium complex (MAC) in people with advanced HIV infection. Rifabutin is also used in combination with other drugs for the treatment of active MAC infections.

Rilpivirine (Edurant): a NON-NUCELOSIDE REVERSE TRANSCRIPTASE INHIBITOR (NNRTI) from Janssen.

Ritonavir (Norvir): a PROTEASE INHIBITOR from Abbott. Ritonavir is commonly used to inhibit the liver enzyme metabolism of other protease inhibitors and improve their blood exposure (“booster”).

Stavudine (Zerit): a NUCLEOSIDE ANALOG from Bristol-Myers Squibb.

Stopped all therapies (Tx): a person in the HIV/AIDS Drug Treatment program that stopped all therapies in this time period and is now CURRENTLY OFF THERAPY.

Stribild: the Gilead trade name for a tablet containing ELVITEGRAVIR, COBICISTAT, EMTRICITABINE and TENOFOVIR DF.

Tenofovir alafenamide (Tenofovir AF, TAF): a NUCLEOTIDE ANALOG from Gilead Sciences with activity against HIV. It is currently available as a component of DESCOVY and GENVOYA.

Tenofovir disoproxil fumarate (Viread, Tenofovir DF, TDF): a NUCLEOTIDE ANALOG from Gilead Sciences with activity against HIV and hepatitis B.

Tipranavir (Aptivus): a PROTEASE INHIBITOR from Boehringer Ingelheim that has activity against HIV in treatment-experienced patients.

Triple Therapy: the use of three drugs, most often a PROTEASE INHIBITOR or NON-NUCLEOSIDE ANALOG with two NUCLEOSIDE ANALOGS, in the treatment of HIV.

Triumeq: the ViiV Healthcare’s trade name for a tablet containing DOLUTEGRAVIR, ABACAVIR and LAMIVUDINE.

Trizivir: the ViiV Healthcare’s trade name for a tablet containing ABACAVIR, ZIDOVUDINE and LAMIVUDINE.

Truvada: the Gilead trade name for a tablet containing TENOFOVIR DF and EMTRICITABINE.

Valganciclovir: an antiviral drug used to treat cytomegalovirus (CMV) retinitis.

Viral Load: the amount of HIV RNA per unit of blood plasma. An indicator of virus concentration and reproduction rate. HIV viral load is employed as a measure of the success of antiretroviral therapy.

Zidovudine (Retrovir): a NUCLEOSIDE ANALOG from ViiV Healthcare. AZT is also approved for preventing maternal-fetal HIV transmission.

